Skip to main content
Clinical Trials/NCT01925781
NCT01925781
Terminated
Phase 4

e-Cigarettes Versus Nicotine Replacement Therapy for Smoking Cessation

Creighton University1 site in 1 country10 target enrollmentAugust 2013

Overview

Phase
Phase 4
Intervention
STAM 1100mAh CE4 eGo Clearomizer
Conditions
Nicotine Addiction
Sponsor
Creighton University
Enrollment
10
Locations
1
Primary Endpoint
Sustained Abstinence
Status
Terminated
Last Updated
10 years ago

Overview

Brief Summary

This is a randomized trial comparing electronic cigarettes (e-Cigarettes) to nicotine gum for smoking cessation. Participants will be randomly assigned to either e-cigarette use or nicotine gum use during a quit attempt. All participants will have a one hour meeting with a tobacco treatment specialist to develop a quit plan and set a quit date. Quit status will be determined at 12 weeks after the quit date. Continued use of nicotine replacement (either e-Cigarette or nicotine gum) and satisfaction with the treatment assignment will be evaluated.

Registry
clinicaltrials.gov
Start Date
August 2013
End Date
November 2013
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Smokes at least five cigarettes per day
  • No current or previous regular use of e-cigarettes
  • Ready to quit smoking

Exclusion Criteria

  • Use of smokeless or pipe tobacco
  • Smoke more than 40 cigarettes per day
  • Pregnant or breastfeeding
  • Unable to chew gum due to dental or jaw problems
  • Myocardial infarction (heart attack) within the previous 12 months
  • Hypersensitivity to propylene glycol or nicotine gum

Arms & Interventions

e-Cigarette

STAM 1100mAh CE4 eGo Clearomizer e-Cigarette

Intervention: STAM 1100mAh CE4 eGo Clearomizer

Nicotine polacrilex

Nicotine Replacement gum

Intervention: Nicotine polacrilex

Outcomes

Primary Outcomes

Sustained Abstinence

Time Frame: 12 weeks

No smoking at 12 weeks after the predetermined quit date with a 5 day grace period. Self-report will be biochemically confirmed with expired carbon monoxide (CO) and salivary cotinine.

Secondary Outcomes

  • Point Prevalence Abstinence(12 weeks)

Study Sites (1)

Loading locations...

Similar Trials